BR112015000971A2 - sistema de liberação de droga flutuante (fdds); e método para prover um sistema de liberação de droga flutuante (fdds) - Google Patents

sistema de liberação de droga flutuante (fdds); e método para prover um sistema de liberação de droga flutuante (fdds)

Info

Publication number
BR112015000971A2
BR112015000971A2 BR112015000971A BR112015000971A BR112015000971A2 BR 112015000971 A2 BR112015000971 A2 BR 112015000971A2 BR 112015000971 A BR112015000971 A BR 112015000971A BR 112015000971 A BR112015000971 A BR 112015000971A BR 112015000971 A2 BR112015000971 A2 BR 112015000971A2
Authority
BR
Brazil
Prior art keywords
fdds
drug release
floating drug
providing
floating
Prior art date
Application number
BR112015000971A
Other languages
English (en)
Inventor
Cornelus Eissens Anko
Willem Frijlink Henderik
Jan Cornelis Meijerink Hendrik
Changoer Lekhram
Regina Visser Marinella
Blom Willem
Original Assignee
Apet Holding B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apet Holding B V filed Critical Apet Holding B V
Priority claimed from PCT/NL2013/050538 external-priority patent/WO2014014348A1/en
Publication of BR112015000971A2 publication Critical patent/BR112015000971A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112015000971A 2011-07-14 2013-07-15 sistema de liberação de droga flutuante (fdds); e método para prover um sistema de liberação de droga flutuante (fdds) BR112015000971A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11173963 2011-07-14
PCT/NL2012/050511 WO2013009186A1 (en) 2011-07-14 2012-07-16 Nicotinamide compositions and the therapeutic use thereof
PCT/NL2013/050538 WO2014014348A1 (en) 2012-07-16 2013-07-15 Gastro-retentive drug delivery system

Publications (1)

Publication Number Publication Date
BR112015000971A2 true BR112015000971A2 (pt) 2017-06-27

Family

ID=44800307

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112014000773A BR112014000773A8 (pt) 2011-07-14 2012-07-16 Composições de nicotinamida e uso terapêutico das mesmas
BR112015000971A BR112015000971A2 (pt) 2011-07-14 2013-07-15 sistema de liberação de droga flutuante (fdds); e método para prover um sistema de liberação de droga flutuante (fdds)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112014000773A BR112014000773A8 (pt) 2011-07-14 2012-07-16 Composições de nicotinamida e uso terapêutico das mesmas

Country Status (7)

Country Link
US (4) US20140234409A1 (pt)
EP (1) EP2731609A1 (pt)
BR (2) BR112014000773A8 (pt)
CA (1) CA2841731A1 (pt)
IL (1) IL236757B (pt)
MX (1) MX2014000517A (pt)
WO (1) WO2013009186A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140234409A1 (en) * 2011-07-14 2014-08-21 APET Holding B.V. Nicotinamide compositions and the therapeutic use thereof
CA3149459A1 (en) * 2012-07-16 2014-01-23 APET Holding B.V. Gastro-retentive drug delivery system
US20140271845A1 (en) * 2013-03-15 2014-09-18 Cerovene, Inc. Coated substrate compositions
WO2018044724A1 (en) * 2016-08-31 2018-03-08 Ampio Pharmaceuticals, Inc. Treatment of disease with n-acetyl kynurenine
EP3398600A1 (en) * 2017-05-02 2018-11-07 Salmon Pharma GmbH Modified release nicotinamide
WO2019027372A1 (en) * 2017-08-02 2019-02-07 Nanyang Technological University FLOATABLE PHARMACEUTICAL MICROCAPSULE COMPOSITION
WO2023166224A1 (en) * 2022-03-04 2023-09-07 APET Holding B.V. Gastroretentive formulations containing protein or peptide

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5512411B2 (pt) * 1974-03-12 1980-04-02
US3976794A (en) 1974-06-03 1976-08-24 Scm Corporation Encapsulation of sugar and its use in sweetened coconut
JPH082781B2 (ja) 1988-10-18 1996-01-17 嘉明 川島 中空顆粒状医薬及びその製法
US4980168A (en) * 1989-10-13 1990-12-25 Natrol, Inc. Dietary supplement for children
US4973467A (en) * 1989-10-13 1990-11-27 Natrol, Inc. Dietary supplement for adults
GB9116610D0 (en) * 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
US8728521B2 (en) * 2005-12-27 2014-05-20 Hemant N. Joshi Physically/molecularly distributed and/or chemically bound medicaments in empty, hard capsule shells
US8784886B2 (en) * 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
BRPI0716481A2 (pt) * 2006-09-04 2014-03-18 Panacea Biotec Ltd Tecnologia de liberação flutuante programável
US20110171275A1 (en) * 2007-08-20 2011-07-14 Team Academy Of Pharmaceutical Science Gastroretentive drug delivery system, preparation method and use thereof
US20090104171A1 (en) 2007-10-19 2009-04-23 Pardee Joel D Metabolic Enhancement Therapy
EP2219775A4 (en) * 2007-12-11 2012-10-03 Univ Nanyang Tech MULTILAYERED HOLLOW MICROSPHERES FOR THE ADMINISTRATION OF HYDROPHILIC ACTIVE COMPOUNDS
KR20110042366A (ko) * 2008-08-18 2011-04-26 팀 아카데미 오브 파마슈티컬 사이언스 위장체류 약물 전달 시스템, 제작 방법 및 그것들의 사용
US20140234409A1 (en) 2011-07-14 2014-08-21 APET Holding B.V. Nicotinamide compositions and the therapeutic use thereof

Also Published As

Publication number Publication date
CA2841731A1 (en) 2013-01-17
EP2731609A1 (en) 2014-05-21
BR112014000773A2 (pt) 2017-06-13
MX2014000517A (es) 2014-07-24
BR112014000773A8 (pt) 2017-10-03
IL236757A0 (en) 2015-03-31
US10881614B2 (en) 2021-01-05
US20150202158A1 (en) 2015-07-23
US20180078503A1 (en) 2018-03-22
IL236757B (en) 2019-06-30
US20180140553A1 (en) 2018-05-24
US20140234409A1 (en) 2014-08-21
WO2013009186A1 (en) 2013-01-17

Similar Documents

Publication Publication Date Title
BR112013021333A2 (pt) sistema médico e método para um procedimento médico
BR112014001368A2 (pt) sistema e método para determinar a localização e a inclinação de membro de engate de guindaste
BR112013022874A2 (pt) sistema e método para prover e transferir dinheiro eletrônico fungível
BR112014012352A2 (pt) sistema para implantar um dispositivo em uma localização distal através de um vaso doente
BR112013011927A2 (pt) sistema e método para atualização de firmware
BR112013033466A2 (pt) uso de um sistema de liberação controlada e sistema de liberação controlada
BR112014022438A2 (pt) método e sistema para determinar uma função de transferência relacionada a cabeçalho e método para determinar um conjunto de funções de transferência relacionadas a cabeçalho acopladas
BR112012031985A2 (pt) método para operar um veículo e sistema de veículo
BR112013013721A2 (pt) tubo, métodos para fabricar um tubo e um sistema de tubo, e, sistema de tubo
BR112013008625A8 (pt) sistema de iluminação de fundo para um monitor
BR112013031508A2 (pt) sistema e método para gerenciamento de um telhado
BR112014003158A2 (pt) método e sistema para determinar a inclinação de um veículo
BR112014012419A2 (pt) método implementado por computador e sistema
BR112013015208A2 (pt) montagem de cateter e um método e sistema para produzir tal montagem
BR112012000888A2 (pt) sistema e método para iniciar um sistema operacional multiambiente
BR112014005333A2 (pt) método e sistema para determinar a localização de um objeto móvel
BR112015000971A2 (pt) sistema de liberação de droga flutuante (fdds); e método para prover um sistema de liberação de droga flutuante (fdds)
BR112012023253A2 (pt) método para formar um sistema de medição de posição e sistema de medição de posição
BRPI1010639A2 (pt) sistema farmacêutico para distribuição transmembrana
BR112014006233A2 (pt) procedimentos otimizados de acesso a sistema
BR112014020972A2 (pt) sistema configurado para prover terapia respiratória a um indivíduo; e método para prover terapia respiratória a um indivíduo
BR112014008229A2 (pt) método e sistema para um conjunto de distribuição de bebida
BR112013014546A2 (pt) dispositivo e método para administração de um dispositivo vascular
BR112013018983A2 (pt) instrumento médico, sistema para calibração de um instrumento médico e método
BR112013003337A2 (pt) apoio de paciente para apoiar um paciente a ser analisado por um sistema de imagem e método

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2523 DE 14-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]